PMC:7080117 / 9290-10281 JSONTXT

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)

Patients (n = 90) Patient demographics   Median age, years (range) 50 (18–86)   Men 39 (43%)   Women 51 (57%) Exposure history   Exposure to Wuhan or infected patient 86 (96%)   Unknown exposure 4 (4%) Comorbid conditions   Any 45 (50%)   Hypertension 17 (19%)   Diabetes 5 (6%)   Cardiovascular disease 3 (3%)   Chronic obstructive pulmonary disease 1 (1%)   Tuberculosis 2 (2%)   Malignancy 2 (2%)   Others 15 (17%) Signs and symptoms   Fever 70 (78%)   Cough 57 (63%)   Sputum production 11 (12%)   Fatigue weakness 19 (21%)   Myalgia 25 (28%)   Sore throat 23 (26%)   Chills 6 (7%)   Headache 4 (4%)   Diarrhea 5 (6%)   Nausea 5 (6%)   Vomit 2 (2%)   No obvious symptoms 6 (7%) Laboratory test   C-reactive protein (mg/L; normal range 0–10)     Increased 38 (42%)     Decreased     Normal 0 (0%) 52 (58%)   Leucocytes (×109/L, normal range 3.5–9.5)     Increased 3 (3%)     Decreased 19 (21%)     Normal 68 (76%)   Positive for (SARS-CoV-2) nucleic acid test by   Real-time PCR 90 (100%)